TopoTarget receives milestone payment from Curagen Corporation  

Danish biopharmaceutical company TopoTarget has received a USD 4.8 mn milestone payment from Curagen Corporation as an ongoing clinical trial of PXD101 is expanded to the US

TopoTarget, a Danish biopharmaceutical company which gained a listing on the Copenhagen Stock Exchange in June, has received a USD 4.8 mn (DKK 29.4 mn) milestone payment from CuraGen Corporation as an ongoing phase II clinical trial of PXD101 is expanded to the US. PXD101 is a small molecule histone deacetylase inhibitor (HDAC) for the treatment of leukaemia.

The phase II trial was commenced in Q1 2005 and is being conducted at multiple sites in Europe; now the US is also being included. The trial is scheduled for completion in mid-2006. During 2005, TopoTarget and Curagen Corporation expect to initiate additional phase II and phase Ib/II studies to investigate PXD101 both as a single agent and in combination with other chemotherapy treatments. The news was reported on the BiotechDenmark and TopoTarget websites.

TopoTarget was established in 2000 and has grown both organically and through acquisitions. In 2002, the company acquired the UK cell cycle company Profilix, and in 2005 the German company G2M Cancer Drugs. TopoTarget is headquartered in Copenhagen and has operations in Oxford UK, and in Frankfurt and Karlsruhe, Germany.

Link > TopoTarget 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×